Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NewBiologix logo — Developing technologies for the biopharma industry to allow...

NewBiologix

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders.

Founded 2023 Switzerland Epalinges, Switzerland 25 employees Series A Total: $45.00M Biotechnology, Health Care +1

General Information

Company Name NewBiologix
Founded Year 2023
Location Switzerland Epalinges, Switzerland
Employees 25
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Business Model B2B, Platform, D2C
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with NewBiologix. To contact NewBiologix, visit newbiologix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NewBiologix compare?

A PDF of NewBiologix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NewBiologix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NewBiologix

NewBiologix, founded in 2023 and headquartered in Lausanne, Switzerland, is positioning itself as a significant contender in the Biotechnology, Health Care, and Life Sciences sectors. The company's mission, encapsulated in their slogan, "Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders," underscores their commitment to transformative healthcare solutions.

Their core innovation, a proprietary DNA integration platform, aims to revolutionize the engineering of human and mammalian cell lines, enhancing the production of viral vectors crucial for gene therapies. This breakthrough has the potential to significantly impact the biopharma industry's approach to disease treatment.

In May 2023, NewBiologix secured a substantial Fr.45.00M Series A investment, backed by notable investors such as Nicolas Mermod, Igor Fish, and the Recipharm Venture Fund. This financial backing supports their ambitious R&D trajectory and expansion plans.

Business keywords: DNA Integration, Gene Therapy, Cell Therapy, Viral Vectors, Genomic Integration, Biopharma Technology, Advanced Cell Engineering, rAAV, Biologics, Stable Cell Lines, Mammalian Cell Lines, Gene Expression, Capsid Optimization, Bioinformatics, Transcriptomics

Services & Products

Xcell™ Genomic Analytical Platform
Xcell™ Eng-HEK293 Cell Line
Xcell™ rAAV Production and Analytics Platform

Target Customers

Biopharmaceutical Companies Gene Therapy Researchers Biotech Entrepreneurs Healthcare Innovators

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Fr.45.00M 3
Nicolas Mermod, Igor Fish +1
11 May 2023

NewBiologix Alternatives & Competitors

View All Alternatives
NewBiologix vs
64x Bio
64x Bio United States

Enabling next generation medicines.

Series A
21 employees
Biopharma, Biotechnology
Compare NewBiologix vs 64x Bio
NewBiologix vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
Compare NewBiologix vs Basilard BioTech, Inc.
NewBiologix vs
4basebio
4basebio United Kingdom

Next generation gene therapy

Grant
102 employees
Biotechnology, Health Care
Also compare with: NewBiologix vs eXmoor pharma eXmoor pharma View all alternatives

FAQ About NewBiologix

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders.
NewBiologix was founded in 2023.
NewBiologix is headquartered in Epalinges, Switzerland.
NewBiologix operates in Biotechnology, Health Care and Life Sciences. Its work centres on DNA Integration, Gene Therapy, Cell Therapy and Viral Vectors. Its customers include Biopharmaceutical Companies, Gene Therapy Researchers and Biotech Entrepreneurs.
NewBiologix has a B2B, Platform and D2C business model. Its revenue comes from Licensing, Product Sales and Service Fee.
NewBiologix has approximately 25 employees.
NewBiologix has completed 1 funding round, raising a total of $45.00M. The latest funding stage is Series A.
NewBiologix offers: Xcell™ Genomic Analytical Platform, Xcell™ Eng-HEK293 Cell Line, Xcell™ rAAV Production and Analytics Platform.
Top alternatives and competitors to NewBiologix include 64x Bio, Basilard BioTech, Inc., 4basebio, Full Circles Therapeutics Inc., Dima Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NewBiologix and 64x Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NewBiologix, https://bouncewatch.com/company/newbiologix, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout